Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

This study is currently recruiting participants. (see Contacts and Locations)

Verified March 2016 by Stanford University

Sponsor:

Information provided by (Responsible Party):

Jean Yuh Tang, Stanford University

ClinicalTrials.gov Identifier:

NCT01019148

First received: November 20, 2009

Last updated: March 17, 2016

Last verified: March 2016

History of Changes

Purpose

Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.

Condition
Epidermolysis Bullosa Dystrophica


Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa

Resource links provided by NLM:

Genetics Home Reference related topics: dystrophic epidermolysis bullosa epidermolysis bullosa simplex epidermolysis bullosa with pyloric atresia junctional epidermolysis bullosa

Genetic and Rare Diseases Information Center resources: Epidermolysis Bullosa Dystrophic Epidermolysis Bullosa

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:

Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa [ Time Frame: 4 years ]
Identification of subjects with Recessive Dystrophic Epidermolysis Bullosa for future studies

Biospecimen Retention: Samples With DNA

Skin biopsies, serum


Estimated Enrollment:	30
Study Start Date:	November 2009
Estimated Study Completion Date:	September 2016
Estimated Primary Completion Date:	September 2016 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients diagnosed with RDEB by a local dermatologist who are medically stable enough to travel to Stanford University Medical Center. Patients should also be at least 7 years of age.

Criteria

Inclusion Criteria:

Clinical diagnosis of RDEB by local dermatologist
7 years of age or older

Exclusion Criteria:

-Medical instability limiting ability to travel to Stanford University Medical Center

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01019148

Contacts


Contact: Kylie Loutit, BS	(650) 721-7166	kloutit@stanford.edu

Locations


United States, California
Stanford University School of Medicine	Recruiting
Stanford, California, United States, 94305
Contact: Kylie Loutit, BS 650-721-7166 kloutit@stanford.edu
Principal Investigator: Jean Tang, MD, PhD
Sub-Investigator: Paul A. Khavari, MD
Sub-Investigator: M. Peter Marinkovich, MD
Sub-Investigator: Anthony Oro, MD
Sub-Investigator: Marius Wernig, MD

Sponsors and Collaborators

Stanford University

Investigators


Principal Investigator:	Jean Tang, MD, PhD	Stanford University

More Information


Responsible Party:	Jean Yuh Tang, Associate Professor, Stanford University
ClinicalTrials.gov Identifier:	NCT01019148 History of Changes
Other Study ID Numbers:	SU-11182009-4402
Study First Received:	November 20, 2009
Last Updated:	March 17, 2016

Additional relevant MeSH terms:


Epidermolysis Bullosa Epidermolysis Bullosa Dystrophica Skin Abnormalities Congenital Abnormalities Skin Diseases, Genetic	Genetic Diseases, Inborn Skin Diseases Skin Diseases, Vesiculobullous Collagen Diseases Connective Tissue Diseases

ClinicalTrials.gov processed this record on May 22, 2017

To Top